Inventors:
Panos Savvides - Boxford MA, US
Norma Terrin - Jamaica Plain MA, US
John Erban - Wakefield MA, US
Harry Selker - Wellesley MA, US
International Classification:
A01N001/00
Abstract:
The invention provides provided a method and instrument for predicting the probability of a patient requiring a significant dose reduction in adjuvant chemotherapy for breast cancer and/or predicting whether early treatment with a myeloid growth factor is warranted, by determining the patient's dose-adjusted nadir absolute neutrophil count (ANC) in the first cycle of the chemotherapy schedule, further determining the patient's dose-adjusted percent change in platelet count from day one to the dose-adjusted nadir platelet count in the first cycle of the chemotherapy schedule, and then calculating the probability that the patient will receive a suboptimal chemotherapy dose using the dose-adjusted nadir ANC and dose-adjusted percent change in platelet count.